Univariate analysis of AML patients according to the most frequent genetic mutations at the level of single genes has shown that FLT3-ITD mutations at the level of single genes have shown that FLT3-ITD mutations represented the primary predictor of outcome in intermediate-risk AML patients (Table 1) [73]. This evidence concerns the gene FLT3 and acute myeloid leukemia.